Instem plc Notice of AGM & Posting of Annual Report (6862L)
May 17 2022 - 2:01AM
UK Regulatory
TIDMINS
RNS Number : 6862L
Instem plc
17 May 2022
Instem plc
("Instem" or the "Company")
Notice of AGM
Posting of Annual Report
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that further to the
announcement of the Company's unaudited results for the year ended
31 December 2021 on 26 April 2022, the audited financial statements
have now been posted to shareholders together with a Notice of
Annual General Meeting. Copies are also available on the Company's
website in the Investor Relations section at:
https://investors.instem.com/docs/
The AGM will be held at 14.00 on 09 June 2022 at Diamond Way,
Stone Business Park, Stone, Staffordshire, ST15 0SD.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser
& Joint Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0)20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management Regulatory Submissions, Clinical Trial Acceleration, and
Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform at some stage of their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAAFMRTMTJBBRT
(END) Dow Jones Newswires
May 17, 2022 02:01 ET (06:01 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Instem (LSE:INS)
Historical Stock Chart
From Oct 2023 to Oct 2024